Điều trị viêm khớp dạng thấp (RA) ở Ấn Độ—cách thức và ai thực hiện: kết quả từ một phòng khám chuyên khoa—việc sử dụng methotrexate liều thấp (MTX) không đạt yêu cầu rõ ràng

Raza K, Buckley CE, Salmon M, Buckley CD (2006) Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol 20:849–863 Demoruelle MK, Deane KD (2012) Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. Curr Rheumatol Rep 14:472–480 Gremese E, Salaffi F, Bosello SL, Ciapetti A, Bobbio-Pallavicini F, Caporali R et al (2013) Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 72:858–862 Smolen JS, Aletaha D, Bijlsma JW (2010) T2T Expert Committee Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631–637 Austad C, Kvien TK, Olsen IC, Uhlig T (2015) Health status has improved more in women than in men with rheumatoid arthritis from 1994 to 2009: results from the Oslo Rheumatoid Arthritis Register. Ann Rheum Dis 74:148–155 Cronstein BN (2005) Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57:163–172 Weinblatt ME (2013) Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc 124:16–25 Weinblatt ME, Kremer JM (2014) Methotrexate use in patients with RA. (Reported Susan Bernstein) ACR/ARHP Annual Meeting: the-rheumatologist.org http://www.the-rheumatologist.org/article/2014-acrarhp-annual-meeting-methotrexate-use-in-patients-with-ra/ Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762–784 Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64:625–639 Braun J (2011) Methotrexate: optimizing the efficacy in rheumatoid arthritis. Ther Adv Musculoskel Dis 3:151–158 Smolen JS et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509 Kay J (2009) Methotrexate: the gold standard without standardisation. Ann Rheum Dis 68:1081–1082 Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J et al (2009) Recommendation: multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68:1086–1093 Visser K, van der Heijde D (2009) Clinical and epidemiological research: optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68:1094–1099 Al-Saeedi S, Keystone EC (2014) Oral or subcutaneous methotrexate for rheumatoid arthritis? Nat Rev Rheumatol 10:578–579 Hazlewood GS, Thorne JC, Pope JE, Lin D, Tin D, Boire G, CATCH investigators et al (2015) The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2014-206504 Bulletin of the World Health Organization: http://www.who.int/bulletin/volumes/88/7/10-020710/en/ Malaviya AN, Gogia SB (2010) Development, implementation and benefits of a rheumatology-specific electronic medical record application with automated display of outcome measures. Int J Rheumatic Dis 13:347–60 Newman ED, Lerch V, Billet J, Berger A, Kirchner HL (2015) Improving the quality of care of patients with rheumatic disease using patient-centric electronic redesign software. Arthritis Care Res (Hoboken) 67:546–553 Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JM, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324 Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23(supplement):S100–S108 Aletaha D, Smolen JS (2007) The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 4:663–675 Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48 Kumar A, Malaviya AN, Pandhi A, Singh R (2002) Validation of an Indian version of the Health Assessment Questionnaire in patients with rheumatoid arthritis. Rheumatology (Oxford) 41:1457–1459 Krishnan E, Sokka T, Häkkinen A, Hubert H, Hannonen P (2004) Normative values for the Health Assessment Questionnaire disability index benchmarking disability in the general population. Arthritis Rheum 50:953–960 Malaviya AN (2015) Glucocorticoid use for rheumatoid arthritis still sparks debate; “to give or not to give? Debate continues over place of glucocorticoids in RA management.” The Rheumatologist. 9(6); http://www.the-rheumatologist.org/article/glucocorticoid-use-for-rheumatoid-arthritis-still-sparks-debate/?singlepage=1&theme=printfriendly Aggarwal R, Malaviya AN (2009) Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes—an Indian perspective. Clin Rheumatol 28:327–331 Crane MM, Juneja M, Allen J, Kurrasch RH, Chu ME, Quattrocchi E, et al. Epidemiology and treatment of new onset and established rheumatoid arthritis in an insured U.S population. Arthritis Care Res DOI 10.1002/acr.22646 Curtis JR, Zang J, Xie F, Beukelman T, Chen L, Fernandes J et al (2014) Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res 66:1604–1611 O’Dell JR, Rohr M, Cohen SB, Thorne JC, Mikuls TR (2015) Underuse of methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) in the United States (US): results of a comprehensive pharmaceutical claims analysis [abstract]. Arthritis Rheumatol. 67 (suppl 10). http://acrabstracts.org/abstract/underuse-of-methotrexate-mtx-in-the-treatment-of-rheumatoid-arthritis-ra-in-the-united-states-us-results-of-a-comprehensive-pharmaceutical-claims-analysis/ Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 33:1449–1461 Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159:2542–2550 Myllykangas-Luosujarvi R, Aho K, Isomaki H (1995) Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. J Rheumatol 22:2214–2217 BRICS (2013) Nations report, http://www.business-standard.com/article/economy-policy/india-s-median-per-capita-income-lowest-among-brics-gallup-113121600968_1.html Pappas DA, Lampl K, Kremer JM, Radominski SC, Gal J, Nyberg F et al. Variations in disease activity and therapeutic management of rheumatoid arthritis in different international regions: a comparison of data from the CORRONA International and CORRONA US Registries [Abstract no. FRI0052]. Handa R, Rao URK, Lewis JFM, Rambhad G, Shiff S, Ghia CJ. Literature review of rheumatoid arthritis in India. Int Jour Rheum Dis doi:10.1111/1756-185X.12621; published on-line on 14th July 2015.